Immunology and Bi...
Follow
Find
8.8K views | +7 today
Immunology and Biotherapies
Page Ressources et Actualités du DIU immunologie et biothérapies
Your new post is loading...
Your new post is loading...
Rescooped by Gilbert Faure au nom de l'ASSIM from Cancer Immunotherapy Review
Scoop.it!

Vaccine immunotherapy in lung cancer: Clinical experience and future directions

Vaccine immunotherapy in lung cancer: Clinical experience and future directions | Immunology and Biotherapies | Scoop.it

Abstract

Lung cancer remains the most common cause of cancer-related deaths in the United States, with SEER data showing lung cancer accounting for 29% of all male-related cancer mortality and 26% of all female-related mortality. Patients with small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) who have localized disease both have 5-year survival rates of 52.2%, whereas patients with metastatic disease have 5-year survival rates of only 3.7%. Traditional anti-cancer therapies (surgery, radiotherapy, and chemotherapy) have limited effectiveness in curbing progression. However, advances in immunology and molecular biology in the past two decades have resulted in improved prognosis for those with SCLC and NSCLC, although novel therapies are still needed to make significant improvements in median overall and progression-free survival rates. Notable progress on the importance of tumor immunology has included work on immune surveillance, antigenic targets, and immune checkpoints. Immunotherapies, including vaccines, which can induce antitumor responses by harnessing the power of the immune system, may help to fill this void, and the cancer vaccine continues to be studied as adjunctive therapy. Here, we review recently reported results from clinical trials as well as the possible future roles of vaccine therapy in the treatment of SCLC and NSCLC patients.


Via Krishan Maggon
more...
Krishan Maggon 's curator insight, August 16, 6:19 AM
Pharmacology & Therapeutics

Volume 153, September 2015, Pages 1–9

 Vaccine immunotherapy in lung cancer: Clinical experience and future directionsMorganna Freeman-Kellera, Jamie Goldmana, Jhanelle Grayb, ,  doi:10.1016/j.pharmthera.2015.05.004
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Stem Cell Therapy: Future of Pain Medicine, Editorial for BJMP | British Journal of Medical Practitioners

Stem Cell Therapy: Future of Pain Medicine, Editorial for BJMP | British Journal of Medical Practitioners | Immunology and Biotherapies | Scoop.it
@GayPatriot http://t.co/uD1x2wqcJ6 Most studies being done overseas due to FDA moving very slow.
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

EHA 2015: The development status of monoclonal antibody-based therapies for multiple myeloma

EHA 2015: The development status of monoclonal antibody-based therapies for multiple myeloma | Immunology and Biotherapies | Scoop.it
At the 20th Congress of the European Hematology Association (EHA), Thierry Facon, MD, of the University Hospital Hurriez, Lille, France, discusses the results of several clinical trials that support an important role for monoclonal antibodies...
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Chimeric antigen receptor T cells for cancer immunotherapy. - PubMed - NCBI

Chimeric antigen receptor T cells for cancer immunotherapy. - PubMed - NCBI | Immunology and Biotherapies | Scoop.it
J Clin Oncol. 2015 May 20;33(15):1703-6. doi: 10.1200/JCO.2014.60.3449. Epub 2015 Apr 20. Comment
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Characterization of Two Human Monoclonal Antibodies Neutralizing Influenza A ... - Journal of Virology

Characterization of Two Human Monoclonal Antibodies Neutralizing Influenza A ...
Journal of Virology
H7N9 was a cause of significant global health concern due to its severe infection and approximately 35% mortality in humans.
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Decellularized human liver as a natural 3D-scaffold for liver bioengineering and transplantation. - PubMed - NCBI

Decellularized human liver as a natural 3D-scaffold for liver bioengineering and transplantation. - PubMed - NCBI | Immunology and Biotherapies | Scoop.it
Sci Rep. 2015 Aug 7;5:13079. doi: 10.1038/srep13079.
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Engineered T Cells for Leukemia: A Review of Current Approaches and Applications - Targeted Oncology

Engineered T Cells for Leukemia: A Review of Current Approaches and Applications - Targeted Oncology | Immunology and Biotherapies | Scoop.it
This review addresses the basics of CAR T-cell design and reviews data from published clinical studies in leukemia.
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Moving MERS Therapies Forward - The Scientist

Moving MERS Therapies Forward - The Scientist | Immunology and Biotherapies | Scoop.it
Scientists wonder whether they can obtain the resources to test experimental vaccines and treatments in humans.
more...
No comment yet.
Rescooped by Gilbert Faure au nom de l'ASSIM from Top Selling Monoclonal Antibodies 2014
Scoop.it!

Fifty Shades of Cancer Immunostimulation, Part 4: Double the Pleasure—Monoclonal Antibodies and Cytokines

Fifty Shades of Cancer Immunostimulation, Part 4: Double the Pleasure—Monoclonal Antibodies and Cytokines | Immunology and Biotherapies | Scoop.it
BY ROBERT G. BELL We continue our discussions with two of the heavyweights of cancer immunotherapies, monoclonal antibodies and cytokines. Monoclonal antibodies (MAbs) for cancer therapies are bioe...

Via Krishan Maggon
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Study of the BCG Vaccine-Induced Cellular Immune Response in Schoolchildren in Antananarivo, Madagascar

Study of the BCG Vaccine-Induced Cellular Immune Response in Schoolchildren in Antananarivo, Madagascar | Immunology and Biotherapies | Scoop.it
by Paulo Ranaivomanana, Vaomalala Raharimanga, Patrice M.
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

New Data Show Pluristem's PLX Cells Regulate the Immune System - CNN Money - CNNMoney

New Data Show Pluristem's PLX Cells Regulate the Immune System - CNN Money - CNNMoney | Immunology and Biotherapies | Scoop.it
New Data Show Pluristem's PLX Cells Regulate the Immune System - CNN Money
CNNMoney
... Berlin-Brandenburg Center for Regenerative Therapy and head of the Institute of Medical Immunology at the Charité.
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

A potent broad-spectrum protective human monoclonal antibody crosslinking two haemagglutinin monomers of influenza A virus : Nature Communications : Nature Publishing Group

A potent broad-spectrum protective human monoclonal antibody crosslinking two haemagglutinin monomers of influenza A virus : Nature Communications : Nature Publishing Group | Immunology and Biotherapies | Scoop.it
New monoclonal antibody might bring us a step closer to pan-influenza protection http://t.co/X4beqDR2qQ
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Aratana Therapeutics Provides Update on Monoclonal Antibody Products - MarketWatch

Aratana Therapeutics Provides Update on Monoclonal Antibody Products - MarketWatch | Immunology and Biotherapies | Scoop.it
Aratana Therapeutics Provides Update on Monoclonal Antibody Products
MarketWatch
Aratana continues its research and development efforts on other monoclonal antibodies in oncology and other therapeutic areas, including MAbs for cats.
Gilbert Faure au nom de l'ASSIM's insight:

your pet deserves MoAbs

more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Correlates of vaccine-induced protection against TB immune revealed in comparative analyses of lymphocyte populations. - PubMed - NCBI

Correlates of vaccine-induced protection against TB immune revealed in comparative analyses of lymphocyte populations. - PubMed - NCBI | Immunology and Biotherapies | Scoop.it
Clin Vaccine Immunol. 2015 Aug 12. pii: CVI.00301-15. [Epub ahead of print]
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Progress in biosimilar monoclonal antibody development: the infliximab biosimilar CT-P13 in the treatment of rheumatic diseases, Immunotherapy, Future Medicine

Progress in biosimilar monoclonal antibody development: the infliximab biosimilar CT-P13 in the treatment of rheumatic diseases, Immunotherapy, Future Medicine | Immunology and Biotherapies | Scoop.it
Progress #biosimilar monoclonal antibody development: infliximab biosimilar CT-P13 in treatment of rheumatic diseases
http://t.co/yk4gWET4JC
more...
No comment yet.
Rescooped by Gilbert Faure au nom de l'ASSIM from Cancer Immunotherapy Review
Scoop.it!

Evolving synergistic combinations of targeted immunotherapies to combat cancer : Nature Reviews Cancer : Nature Publishing Group

Evolving synergistic combinations of targeted immunotherapies to combat cancer : Nature Reviews Cancer : Nature Publishing Group | Immunology and Biotherapies | Scoop.it

Abstract

Immunotherapy has now been clinically validated as an effective treatment for many cancers. There is tremendous potential for synergistic combinations of immunotherapy agents and for combining immunotherapy agents with conventional cancer treatments. Clinical trials combining blockade of cytotoxic T lymphocyte-associated antigen 4 (CTLA4) and programmed cell death protein 1 (PD1) may serve as a paradigm to guide future approaches to immuno-oncology combination therapy. In this Review, we discuss progress in the synergistic design of immune-targeting combination therapies and highlight the challenges involved in tailoring such strategies to provide maximal benefit to patients.


Via Krishan Maggon
more...
Krishan Maggon 's curator insight, August 14, 7:09 AM

NATURE REVIEWS CANCER | REVIEW

Evolving synergistic combinations of targeted immunotherapies to combat cancerIgnacio Melero,David M. Berman,M. Angela Aznar,Alan J. Korman,José Luis Pérez Gracia& John HaanenAffiliationsCorresponding authorNature Reviews Cancer 15, 457–472 (2015) doi:10.1038/nrc3973Published online 24 July 2015
Sean McGrath's curator insight, August 14, 8:59 AM

It seems to me that we are making real progress in IO, and when we combine different strategies of boosting the body's defence systems, I believe we will have yet greater success

Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Association of antibody induction immunosuppression with cancer after kidney transplantation. - PubMed - NCBI

Association of antibody induction immunosuppression with cancer after kidney transplantation. - PubMed - NCBI | Immunology and Biotherapies | Scoop.it
Transplantation. 2015 May;99(5):1051-7. doi: 10.1097/TP.0000000000000449. Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Burkholderia pseudomallei Capsular Polysaccharide Recognition by a Monoclonal Antibody Reveals Key Details toward a Biodefense Vaccine and Diagnostics against Melioidosis - ACS Chemical Biology (AC...

Burkholderia pseudomallei Capsular Polysaccharide Recognition by a Monoclonal Antibody Reveals Key Details toward a Biodefense Vaccine and Diagnostics against Melioidosis - ACS Chemical Biology (AC... | Immunology and Biotherapies | Scoop.it
Burkholderia pseudomallei Capsular Polysaccharide Recognition by a Monoclonal Antibody… http://t.co/HlqndacLBG
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Toward understanding and exploiting tumor heterogeneity - Nature.com

Nature.com Toward understanding and exploiting tumor heterogeneity Nature.com Recent data suggest that the sustained benefit of radiation combined with blockade of cytotoxic T lymphocyte–associated protein 4 (CTLA4) may also require blockade of...
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Novel monoclonal antibody-based therapies for multiple myeloma | Prof Sagar Lonial at EHA 2015

Novel monoclonal antibody-based therapies for multiple myeloma | Prof Sagar Lonial at EHA 2015 | Immunology and Biotherapies | Scoop.it
At the 20th Congress of the European Hematology Association (EHA), Sagar Lonial, MD, of the Winship Cancer Institute, Emory University, Atlanta, GA, discusses promising monoclonal antibodies in clinical development for the treatment of patients...
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Vaccinology

Vaccinology | Immunology and Biotherapies | Scoop.it
This course (in english, subtitled in french) offers an integrated overview of vaccinology, from public health and scientific data justifying the development of a vaccine, to its delivery to the populations
more...
No comment yet.
Rescooped by Gilbert Faure au nom de l'ASSIM from Cancer Immunotherapy Review
Scoop.it!

Frontiers | Editorial: “Cancer Immunotherapy: Lights and Shadows” | Immunotherapies and Vaccines

Frontiers | Editorial: “Cancer Immunotherapy: Lights and Shadows” | Immunotherapies and Vaccines | Immunology and Biotherapies | Scoop.it
Cancer immunotherapy has recently emerged as the fourth treatment modality, in addition to surgery, chemotherapy and radiotherapy. These advances are the result of important discoveries in the fiel...

Via Krishan Maggon
more...
Krishan Maggon 's curator insight, July 29, 1:05 PM
EDITORIAL ARTICLEFront. Immunol., 07 July 2015 | http://dx.doi.org/10.3389/fimmu.2015.00350Editorial: “Cancer immunotherapy: lights and shadows”María Marcela Barrio1, Estrella Mariel Levy1 and José Mordoh1,2,3*1Fundación Cáncer FUCA, Centro de Investigaciones Oncológicas, Buenos Aires, Argentina2Fundación Instituto Leloir, Buenos Aires, Argentina3Instituto Alexander Fleming, Buenos Aires, Argentina
Rescooped by Gilbert Faure au nom de l'ASSIM from Cancer Immunotherapy Review
Scoop.it!

Engineered materials for cancer immunotherapy

Engineered materials for cancer immunotherapy | Immunology and Biotherapies | Scoop.it

Via Krishan Maggon
more...
Krishan Maggon 's curator insight, July 29, 5:37 AM

Available online 15 July 2015

In Press, Corrected Proof — Note to users

Review Engineered materials for cancer immunotherapyAlexander S. Cheung, David J. Mooney,   doi:10.1016/j.nantod.2015.06.007
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Adalimumab for the treatment of pediatric Crohn’s disease, Expert Review of Clinical Immunology, Informa Healthcare

Adalimumab for the treatment of pediatric Crohn’s disease, Expert Review of Clinical Immunology, Informa Healthcare | Immunology and Biotherapies | Scoop.it
Adalimumab for the treatment of pediatric Crohn’s disease: Expert Review of Clinical Immunology, Ahead of Print.
http://t.co/2cFoujNCY8
more...
No comment yet.
Rescooped by Gilbert Faure au nom de l'ASSIM from Top Selling Monoclonal Antibodies 2014
Scoop.it!

Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease — NEJM

Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease — NEJM | Immunology and Biotherapies | Scoop.it
Original Article from The New England Journal of Medicine — Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease

 

BACKGROUND

A candidate tetravalent dengue vaccine is being assessed in three clinical trials involving more than 35,000 children between the ages of 2 and 16 years in Asian–Pacific and Latin American countries. We report the results of long-term follow-up interim analyses and integrated efficacy analyses.

Full Text of Background...

 METHODS

We are assessing the incidence of hospitalization for virologically confirmed dengue as a surrogate safety end point during follow-up in years 3 to 6 of two phase 3 trials, CYD14 and CYD15, and a phase 2b trial, CYD23/57. We estimated vaccine efficacy using pooled data from the first 25 months of CYD14 and CYD15.

Full Text of Methods...

 RESULTS

Follow-up data were available for 10,165 of 10,275 participants (99%) in CYD14 and 19,898 of 20,869 participants (95%) in CYD15. Data were available for 3203 of the 4002 participants (80%) in the CYD23 trial included in CYD57. During year 3 in the CYD14, CYD15, and CYD57 trials combined, hospitalization for virologically confirmed dengue occurred in 65 of 22,177 participants in the vaccine group and 39 of 11,089 participants in the control group. Pooled relative risks of hospitalization for dengue were 0.84 (95% confidence interval [CI], 0.56 to 1.24) among all participants, 1.58 (95% CI, 0.83 to 3.02) among those under the age of 9 years, and 0.50 (95% CI, 0.29 to 0.86) among those 9 years of age or older. During year 3, hospitalization for severe dengue, as defined by the independent data monitoring committee criteria, occurred in 18 of 22,177 participants in the vaccine group and 6 of 11,089 participants in the control group. Pooled rates of efficacy for symptomatic dengue during the first 25 months were 60.3% (95% CI, 55.7 to 64.5) for all participants, 65.6% (95% CI, 60.7 to 69.9) for those 9 years of age or older, and 44.6% (95% CI, 31.6 to 55.0) for those younger than 9 years of age.

Full Text of Results...

 CONCLUSIONS

Although the unexplained higher incidence of hospitalization for dengue in year 3 among children younger than 9 years of age needs to be carefully monitored during long-term follow-up, the risk among children 2 to 16 years of age was lower in the vaccine group than in the control group. (Funded by Sanofi Pasteur; ClinicalTrials.gov numbers, NCT00842530, NCT01983553, NCT01373281, andNCT01374516.)


Via Krishan Maggon
Gilbert Faure au nom de l'ASSIM's insight:

major clinical research for mundial population

more...
Krishan Maggon 's curator insight, July 27, 2:57 PM

ORIGINAL ARTICLE

Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease

Sri Rezeki Hadinegoro, M.D., Ph.D., Jose Luis Arredondo-García, M.D., Maria Rosario Capeding, M.D., Carmen Deseda, M.D., Tawee Chotpitayasunondh, M.D., Reynaldo Dietze, M.D., H.I. Hj Muhammad Ismail, M.B., B.S., Humberto Reynales, M.D., Ph.D., Kriengsak Limkittikul, M.D., Doris Maribel Rivera-Medina, M.D., Huu Ngoc Tran, M.D., Ph.D., Alain Bouckenooghe, M.D., Danaya Chansinghakul, M.D., Margarita Cortés, M.D., Karen Fanouillere, M.Sc., M.P.H., Remi Forrat, M.D., Carina Frago, M.D., Sophia Gailhardou, Pharm.D., Nicholas Jackson, Ph.D., Fernando Noriega, M.D., Eric Plennevaux, Ph.D., T. Anh Wartel, M.D., Betzana Zambrano, M.D., and Melanie Saville, M.B., B.S. for the CYD-TDV Dengue Vaccine Working Group

July 27, 2015DOI: 10.1056/NEJMoa1506223